NEW YORK (GenomeWeb News) - Illumina today said that it signed a definitive agreement to acquire Verinata Health for $350 million with additional potential milestone payments of up to $100 million through 2015.

The deal provides Illumina with Verinata’s Verifi non-invasive prenatal test for detecting trisomy 21, 18, and 13. The test analyzes cell-free fetal DNA using next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.